Paul S Harper, MD | |
675 Biltmore Ave, Suite A, Asheville, NC 28803-2459 | |
(828) 250-0181 | |
(828) 250-0142 |
Full Name | Paul S Harper |
---|---|
Gender | Male |
Speciality | Nuclear Medicine |
Location | 675 Biltmore Ave, Asheville, North Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1053332866 | NPI | - | NPPES |
183580 | Other | NC | MEDCOST |
39596 | Other | NC | BCBS |
8939596 | Medicaid | NC |
Mailing Address | Practice Location Address |
---|---|
Paul S Harper, MD 3480 Preston Ridge Rd Ste 600, Credentialing Dept, Alpharetta, GA 30005-5462 Ph: (770) 300-0101 | Paul S Harper, MD 675 Biltmore Ave, Suite A, Asheville, NC 28803-2459 Ph: (828) 250-0181 |
News Archive
Bacteria are among the simplest organisms in nature, but many of them can still talk to each other, using a chemical "language" that is critical to the process of infection. Sending and receiving chemical signals allows bacteria to mind their own business when they are scarce and vulnerable, and then mount an attack after they become numerous enough to overwhelm the host's immune system.
Clinicians should consider screening for hepatitis C virus in all patients born between 1945 and 1965, the US Preventive Services Task Force says in draft guidance.
While the world waits eagerly for a safe and effective vaccine to prevent infections from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus behind the COVID-19 pandemic, researchers also are focusing on better understanding how SARS-CoV-2 attacks the body in the search for other means of stopping its devastating impact.
For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy.
Results from the HEBE III study, a prospective, randomised, multicentre trial performed in seven centres in the Netherlands, suggest that the promising effects of erythropoieitin seen in previous smaller studies cannot be confirmed for the improvement of clinical outcome in patients with a first ST-elevation myocardial infarction.
› Verified 8 days ago